Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M36,658Revenue $M2,234Net Margin (%)29.4Z-Score26.8
Enterprise Value $M34,816EPS $3.3Operating Margin %38.9F-Score8
P/E(ttm))55.5Cash Flow Per Share $0.8Pre-tax Margin (%)39.0Higher ROA y-yY
Price/Book10.910-y EBITDA Growth Rate %0Quick Ratio4.3Cash flow > EarningsN
Price/Sales16.45-y EBITDA Growth Rate %52.3Current Ratio4.6Lower Leverage y-yY
Price/Cash Flow115y-y EBITDA Growth Rate %63.8ROA % (ttm)17.9Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)22.8Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M202ROI % (ttm)16.0Gross Margin Increase y-yY

Gurus Latest Trades with ALXN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALXNJoel Greenblatt 2014-12-31 Add0.13%$159.46 - $200.79
($185.68)
$ 181.34-2%Add 4665.74%85,974
ALXNRon Baron 2014-12-31 Add$159.46 - $200.79
($185.68)
$ 181.34-2%Add 41.92%18,366
ALXNJoel Greenblatt 2014-09-30 Reduce-0.03%$155.06 - $173.08
($164.22)
$ 181.349%Reduce -89.45%1,804
ALXNRon Baron 2014-09-30 Add$155.06 - $173.08
($164.22)
$ 181.349%Add 27.56%12,941
ALXNJoel Greenblatt 2014-06-30 Add0.02%$139.61 - $170.2
($157.93)
$ 181.3413%Add 240.11%17,094
ALXNRon Baron 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 181.3413%New holding10,218
ALXNJoel Greenblatt 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 181.3413%New holding5,026
ALXNJoel Greenblatt 2013-03-31 Sold Out -0.07%$83.39 - $102.57
($93.13)
$ 181.3449%Sold Out0
ALXNJoel Greenblatt 2012-12-31 Buy 0.07%$87.97 - $118.15
($98.27)
$ 181.3446%New holding12,977
ALXNGeorge Soros 2012-06-30 Sold Out -0.07%$83.74 - $98.82
($91.04)
$ 181.3450%Sold Out0
ALXNGeorge Soros 2012-03-31 Buy 0.07%$70.29 - $94.31
($75.85)
$ 181.3458%New holding50,000
ALXNJoel Greenblatt 2011-09-30 Sold Out -0.0882%$47.81 - $66.99
($56.19)
$ 181.3469%Sold Out0
ALXNJoel Greenblatt 2011-06-30 Buy 0.09%$44.61 - $52.195
($47.91)
$ 181.3474%New holding13,417
ALXNGeorge Soros 2011-06-30 Sold Out $44.61 - $52.195
($47.91)
$ 181.3474%Sold Out0
ALXNGeorge Soros 2011-03-31 Add$20.14 - $24.93
($22.51)
$ 181.3488%Add 90.48%16,000
ALXNGeorge Soros 2010-12-31 Reduce$31.78 - $41.17
($36.65)
$ 181.3480%Reduce -87.61%4,200
ALXNGeorge Soros 2010-09-30 Buy 0.03%$24.99 - $32.49
($28.22)
$ 181.3484%New holding33,900
ALXNGeorge Soros 2010-06-30 Sold Out -0.17%$24.31 - $28.34
($26.54)
$ 181.3485%Sold Out0
ALXNGeorge Soros 2010-03-31 Add0.06%$22.75 - $27.7
($24.88)
$ 181.3486%Add 51.77%214,000
ALXNGeorge Soros 2009-12-31 Buy 0.1%$21.65 - $24.33
($22.8)
$ 181.3487%New holding141,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALXN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ALXN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BELL LEONARDCEO 2015-03-19Sell15,952$188.07-2.75view
Sinha VikasEVP & CFO 2015-03-02Sell487$180.341.42view
O'Neill JulieEVP. Global Operations 2015-03-02Sell11,665$101.4980.21view
MACKAY MARTINEVP & Global Head of R&D 2015-03-02Sell370$180.341.42view
Moriarty John BEVP & General Counsel 2015-03-02Sell280$180.341.42view
Islam SaqibEVP, Chief Strat & Port. Off. 2015-03-02Sell228$180.341.42view
Carmichael ClareEVP, Chief HR Officer 2015-03-02Sell706$180.341.42view
Hallal DavidCOO 2015-03-02Sell730$180.341.42view
BELL LEONARDCEO 2015-03-02Sell1,230$180.341.42view
Sinha VikasEVP & CFO 2015-02-10Sell1,985$171.156.87view

Press Releases about ALXN :

    Quarterly/Annual Reports about ALXN:

    News about ALXN:

    Articles On GuruFocus.com
    Alexion Pharma Downgraded Despite Progress in Pipeline Jan 05 2015 
    Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc. Dec 08 2014 
    Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
    CEO of Alexion Pharmaceuticals Sells Company Stock Sep 29 2014 
    Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014 
    Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
    Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 10 2014 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Six High-Impact Sells - Viking Global Investors Aug 27 2013 
    CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares Aug 19 2013 

    More From Our Partners
    Alexion Up as Soliris Gains EU Nod for Label Updates - Analyst Blog Apr 13 2015 - ZACKS

    More From Other Websites
    Alexion Up as Soliris Gains EU Nod for Label Updates - Analyst Blog Apr 13 2015
    Alexion Announces Presentations at 2015 American Transplant Congress, Including Results from Studies... Apr 13 2015
    2:49 am Alexion Pharma receives approval for important updates to the European Label for Soliris Apr 12 2015
    Alexion Receives Approval for Important Updates to the European Label for Soliris® (eculizumab) Apr 10 2015
    Alexion Pharmaceuticals to Report First Quarter 2015 Results on Thursday, April 23, 2015 Apr 09 2015
    Alexion Pharmaceuticals to Report First Quarter 2015 Results on Thursday, April 23, 2015 Apr 09 2015
    ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Apr 07 2015
    These 10 Pharma and Health Care Stocks Were the Worst S&P 500 Performers Last Quarter Apr 02 2015
    Economic Indicators Move Equities and Bonds Apr 01 2015
    3 Top-Rated Biotechs Could Take Buy Points Soon Mar 31 2015
    Why Citigroup Removed Gilead Sciences From Its 'Most Preferred' List Mar 30 2015
    ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 26 2015
    One analyst is convinced the biotech stock plunge is 'misguided' Mar 26 2015
    Two Healthcare Stocks Provide Antidotes To Wild Market Swings Mar 24 2015
    ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Mar 16 2015
    Affymetrix Hits 52-Week High on Stellar Q4, Positive Outlook - Analyst Blog Mar 13 2015
    Analyst: Alexion Pharmaceuticals Pipeline Is Undervalued Mar 11 2015
    New Data from First Natural History Study in Juveniles with Hypophosphatasia (HPP) Showing... Mar 07 2015
    FDA Grants Priority Review for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia Mar 02 2015
    FDA Grants Priority Review for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia Mar 02 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK